Table 4. Hazard ratios of probable Alzheimer's disease development among ε4 carriers.

Predictor variables	Analytic sample size	ε4 carrier Main effects (unadjusted) Hazard ratio (95% CI)	ε4 carrier Main effects adjusteda Hazard ratio (95% CI)	ε4 carrier Main effects adjusted with AD medication use Hazard ratio (95% CI)
ε4 carrier	2470	2.07 (1.63–2.64)**	2.77 (2.16–3.56)**	2.19 (1.70–2.82)**
Use of an antidepressant	1713	2.15 (1.43–3.24)**	2.77 (1.80–4.25)**	1.99 (1.29–3.08)*
Did not use antidepressant		1.93 (1.43–2.61)**	2.55 (1.86–3.48)**	2.24 (1.64–3.07)**
Used bupropion	241	1.69 (0.453–6.33)	2.41 (0.465–12.50)	2.63 (0.394–17.51)
Did not use bupropion		2.08 (1.63–2.66)**	2.77 (2.15–3.58)**	2.22 (1.71–2.87)**
Used citalopram	304	3.89 (1.76–8.60)**	5.10 (2.21–11.80)**	2.79 (1.14–6.80)*
Did not use citalopram		1.94 1.50–2.50)**	2.62 (2.01–3.41)**	2.13 (1.63–2.78)**
Used escitalopram	233	1.44 (0.537–3.84)	1.93 (0.669–5.58)	0.631 (0.194–2.05)
Did not use escitalopram		2.10 (1.64–2.70)**	2.79 (2.16–3.62)**	2.26 (1.74–2.93)**
Used fluoxetine	189	1.55 (0.097–24.78)	—	—
Did not use fluoxetine		2.08 (1.63–2.65)**	2.78 (2.16–3.58)**	2.19 (1.70–2.82)**
Used mirtazapine	98	0.576 (0.136–2.43)	0.877 (0.122–6.30)	6.09 (0.331–112.26)
Did not use mirtazapine		2.12 (1.66–2.71)**	2.81 (2.1–3.63)**	2.17 (1.68–2.81)**
Used paroxetine	125	4.76 (1.04–21.83)*	5.66 (1.10–29.14)*	6.21 (1.14–33.91)*
Did not use paroxetine		2.04 (1.60–2.60)**	2.73 (2.12–3.53)**	2.14 (1.66–2.77)**
Used sertraline	296	0.694 (0.183–2.62)	0.886 (0.196–4.00)	0.961 (0.194–4.75)
Did not use sertraline		2.16 (1.69–2.77)**	2.88 (2.23–3.72)**	2.34 (1.80–3.02)**
Used trazodone	217	2.30 (0.737–7.16)	3.98 (1.03–15.33)*	3.29 (0.694–15.59)
Did not use trazodone		2.06 (1.61–2.64)**	2.72 (2.11–3.52)**	2.18 (1.68–2.82)**

^—indicates sample size too small for analysis.

^aAdjusted for sex, age, education, and race.

^*Statistical significance at p < 0.05.

^**p < 0.001.